Streetwise Reports' Article Archives — March 2018 back to current month (10)
Medical Device Firm Posts 'Strong Performance' Globally in Q4/17 (03/28/2018)
The company performed strongly in the U.S. and the Asia Pacific region.
Regrouped Biotech's Stock Price Could See Fifteenfold Increase (03/28/2018)
A recent conference call provided clinical and financial updates.
Convergence Will Drive the Ultimate Disruption of Life Sciences (03/28/2018)
Andrea Bartzen, a strategic commercial and communication consultant, describes the disruptive technologies positioned to radically alter the business of life sciences as discussed at a recent BIO CEO Summit Investor Night.
Two Biotechs Earn Analyst's Top Pick Ranking (03/19/2018)
Echelon Wealth Partners analyst Doug Loe sees blue sky potential for one company's newly approved HIV compound, while the vaccine platform of a second company earned it Top Pick status as well.
Price Target on Biotech Is a 700% Potential Increase (03/19/2018)
Ram Selvaraju, an analyst with H.C. Wainwright & Co., explained Phase 2 data recently released by this company, which documented improvements in patients with inflammatory bowel disease.
Biotech's Encouraging Phase 2 Gut Microbiome Data 'Bodes Well' for Phase 3 (03/14/2018)
H.C. Wainwright & Co. analyst Ram Selvaraju reported the latest study findings involving this biotherapeutic firm's lead asset.
Coverage Initiated on Biotech; Analyst Says, 'Time to Buy' (03/14/2018)
Sarah Weber, an analyst with Piper Jaffray & Co., made the case for investing in this biotherapeutic development firm.
Coverage Initiated on Biotech with Interference RNA Platform; Target Price Shows 600% Upside (03/07/2018)
John Vandermosten, an analyst with Zacks Small-Cap Research, analyzed this therapeutics development firm as an investment.
Biotech Launches Trial Dosing Against Backdrop of Strong Balance Sheet (03/07/2018)
Four analysts provided updates regarding the status of this firm's financials and one of its clinical programs.
Exciting Biotech Stock Now Breaking Out of Large Base (03/05/2018)
Technical analyst Clive Maund takes a look at a biotech stock that he views as a strong buy.
2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2020Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2019Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec